meta
|
evidence
oncology
Living systematic review and meta-analysis
malignant mesothelioma (mMS) - 2nd line (L2)
2
multiple myeloma
immune chekpoint inhibitors
anti-CTLA-4
tremelimumab
anti-PD-(L)1
nivolumab based treatment
nivolumab alone